B6;129S2-Tcra^tm1Mom/J

Stock number: 002115
Research areas: Hematological Research, Immunology, Inflammation and Autoimmunity Research, Research Tools

Description

Mice homozygous mice for the Tcra^tm1Mom targeted mutation are deficient in the alpha beta T-cell receptor. The thymus is devoid of CD4⁺CD8^- and CD4^-CD8⁺ cells. Mice may develop inflammatory bowel disease beginning at ~4-6 months of age.

Detailed description

Mice homozygous mice for the Tcra^tm1Mom targeted mutation are viable and fertile. They are deficient in the alpha beta T-cell receptor. The thymus is devoid of CD4⁺CD8^- and CD4^-CD8⁺ cells. Normal numbers of CD4⁺CD8⁺ cells are retained without the IL2 receptor. There are normal numbers of CD4^-CD8^- cells. ~1% of the thymocytes express the gamma delta TCR. Mice may develop inflammatory bowel disease beginning at ~4-6 months of age.

Development

The Tcra^tm1Mom mutant strain was developed by Dr. Peter Mombaerts in the laboratory of Dr. Susumu Tonegawa at the Center for Cancer Research, Massachusetts Institute of Technology. A targeting vector with the Pgk-neo gene disrupting exon 1 of Tcra was used. The 129-derived D3 ES cell line was used.

Allele

Symbol: Tcra^tm1Mom
Name: targeted mutation 1, Peter Mombaerts
MGI accession ID: MGI:1857255
Generation method: Targeted
Attributes: Null/Knockout
Synonyms: TCR alpha-; C-alpha-; TCRalpha-; TCR alpha⁰; alpha^-; TCRalpha KO; TCR Calpha^-; TCR^mini
Marker symbol: Tcra
Marker name: T cell receptor alpha chain
Chromosome: 14
Strain of origin: 129S2/SvPas
Molecular note: A PGK-neo cassette was used to disrupt exon 1, which encodes the majority of the extracellular domain. The targeting event was confirmed by Southern analysis.